This meta-analysis of observational studies suggests that combining SGLT2 inhibitors and GLP-1 RAs in individuals with type 2 diabetes may lower the risk of MACE, all-cause and cardiovascular mortality, adverse kidney outcomes, hospitalisation for heart failure, stroke and myocardial infarction. Here, SLC5A2 is linked to type 2 diabetes mellitus.